{
  "slug": "eugit-therapeutics",
  "name": "Eugit Therapeutics",
  "yc_id": 26427,
  "batch": "Summer 2022",
  "website": "http://www.eugittx.com",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:16:19.401929",
    "website": "http://www.eugittx.com",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 3355.05,
      "final_url": "https://www.eugittx.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:16:22.756988"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "eugittx.com",
      "registrar": "Squarespace Domains II LLC",
      "creation_date": "2021-12-30T18:12:28",
      "expiration_date": "2025-12-30T18:12:28",
      "domain_age_days": 1386,
      "domain_age_years": 3.8,
      "name_servers": [
        "NS-CLOUD-D1.GOOGLEDOMAINS.COM",
        "NS-CLOUD-D2.GOOGLEDOMAINS.COM",
        "NS-CLOUD-D3.GOOGLEDOMAINS.COM",
        "NS-CLOUD-D4.GOOGLEDOMAINS.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": false,
      "x_frame_options": true,
      "x_content_type_options": true,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 50,
      "server": "Squarespace"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:45.483439",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:52:27.637717",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Precision medicine adoption accelerating",
        "Targeted drug delivery technologies advancing",
        "IBD prevalence increasing globally"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Novel T cell receptor-based targeting technology with George Church's scientific credibility",
      "differentiation": "TAGHOME platform uses T cell receptors for tissue-specific drug delivery vs traditional antibody-based approaches",
      "competitive_advantages": [
        "George Church co-founder credibility",
        "Novel TCR-based targeting mechanism"
      ],
      "competitive_vulnerabilities": [
        "Small team size",
        "Early-stage technology validation"
      ]
    },
    "business_model": {
      "revenue_model": "biotech licensing/partnerships",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Y Combinator backing",
        "Clear clinical timeline (2 years to trials)"
      ],
      "growth_bottlenecks": [
        "Regulatory approval timelines",
        "Clinical trial funding requirements"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 7,
      "key_risks": [
        "Unproven technology platform",
        "Long development timelines",
        "Regulatory approval uncertainty"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "World-class scientific founder",
        "Large addressable market",
        "Clear unmet medical need"
      ],
      "concerns": [
        "Very early stage technology",
        "Small team for complex biotech execution"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Moderna",
        "Ginkgo Bioworks"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Expand scientific team",
        "Secure additional funding for clinical trials"
      ],
      "expansion_opportunities": [
        "Other inflammatory diseases beyond IBD",
        "Platform licensing to pharma partners"
      ]
    },
    "tokens_used": {
      "input": 743,
      "output": 521,
      "total": 1264,
      "estimated_cost": 0.010044
    },
    "status": "success"
  },
  "phase8_complete": true
}